MicroPort Scientific : ® Broadcasted Two Complex Operations with Firehawk® i...

Paris, France - On May 17, a live case using Firehawk Rapamycin Target Eluting Coronary Stent System ('Firehawk') to treat high-risk bifurcation disease was broadcasted at EuroPCR in Paris. Firehawk is a drug-eluting stent in-house developed by Shanghai MicroPort Medical (Group) Co., Ltd. ('MicroPort').

The two operations were conducted respectively by expert team from Fuwai Hospital of Chinese Academy of Medical Sciences and the Elisabeth Hospital in Germany. Specifically, Professor Yuejin Yang of Fuwai Hospital of Chinese Academy of Medical Sciences and his team performed an operation treating LM bifurcation disease and Dr. Christopher Naber of the Elisabeth Hospital used Firehawk to treat LAD bifurcation disease. Both team chose to adopt the mini crush technique. In the operations of exemplary and educational importance, the two experts fully demonstrated the key points and strategies in the treatment of bifurcation disease. The two operations achieved successful outcome and the safety and efficacy of Firehawk were highly recognized by experts in attendance.

The advancement in R&D innovation of Asian interventional devices has deeply impacted the US and European markets, and Asia may lead the industry in medical device innovations in the future. Dr. Linda Lin, First Vice President of International Business, said: 'As a leading high-end medical device provider in China and Asia, MicroPort will constantly strive for innovations, to provide better medical solutions to China and the world and benefit more patients with coronary heart diseases.'

About MicroPort

MicroPort Scientific Corporation (the 'Group') is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 15 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to: www.microport.com

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words 'believe', 'intend', 'expect', anticipate', 'project', 'estimate', 'predict', 'is confident', 'has confidence' and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort's management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 2017 MicroPort Scientific Corporation